Clearmind Medicine Inc. Common Shares (CMND) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Clearmind Medicine Inc. Common Shares (CMND) has a cash flow conversion efficiency ratio of -0.253x as of January 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.08 Million) by net assets ($8.23 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Clearmind Medicine Inc. Common Shares - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Clearmind Medicine Inc. Common Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Clearmind Medicine Inc. Common Shares balance sheet liabilities for a breakdown of total debt and financial obligations.
Clearmind Medicine Inc. Common Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Clearmind Medicine Inc. Common Shares ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Boqii Holding Limited
NYSE:BQ
|
0.002x |
|
Eminence Minerals Limited
AU:EMA
|
-0.112x |
|
Alpha Compute Corp
NASDAQ:ALP
|
-0.080x |
|
Eezy PLC
HE:EEZY
|
0.056x |
|
Gencell Ltd
TA:GNCL
|
-0.577x |
|
UNIDOC HEALTH CORP.
F:L7T
|
41.739x |
|
N1 Holdings Ltd
AU:N1H
|
8.014x |
|
Thunderstruck Resources Ltd
V:AWE
|
-0.004x |
Annual Cash Flow Conversion Efficiency for Clearmind Medicine Inc. Common Shares (2014–2025)
The table below shows the annual cash flow conversion efficiency of Clearmind Medicine Inc. Common Shares from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see CMND company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-10-31 | $1.19 Million | $-4.73 Million | -3.970x | -153.91% |
| 2024-10-31 | $4.33 Million | $-6.76 Million | -1.564x | +75.60% |
| 2023-10-31 | $983.47K | $-6.30 Million | -6.407x | -290.27% |
| 2022-10-31 | $-1.50 Million | $-5.06 Million | 3.368x | +728.19% |
| 2021-10-31 | $3.87 Million | $-2.08 Million | -0.536x | -1.21% |
| 2020-10-31 | $374.78K | $-198.50K | -0.530x | -12.49% |
| 2019-10-31 | $101.63K | $-47.85K | -0.471x | -6.62% |
| 2018-10-31 | $182.24K | $-80.48K | -0.442x | -138.92% |
| 2017-10-31 | $49.36K | $-9.12K | -0.185x | -154.96% |
| 2016-10-31 | $-45.71K | $-15.37K | 0.336x | -81.84% |
| 2015-10-31 | $-21.49K | $-39.81K | 1.852x | +23.23% |
| 2014-10-31 | $-18.64K | $-28.01K | 1.503x | -- |
About Clearmind Medicine Inc. Common Shares
Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression. It d… Read more